edoxaban

(redirected from Savaysa)
Also found in: Medical.
Related to Savaysa: edoxaban, Eliquis
Translations

edoxaban

n edoxabán m
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
Within the DOAC-treated group, 42% received rivaroxaban (Xarelto), 26% dabigatran (Pradaxa), 24% apixaban (Eliquis), and 8% edoxaban (Savaysa).
The procedure can be performed in your doctor's office, but it is not suitable for people who take blood thinners, such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Savaysa).
Several other drugs, such as edoxaban (Savaysa) and rivaroxaban (Xarelto) also are available, with no monitoring, blood testing, or dietary restrictions necessary.
These agents, which include the factor Xa inhibitors rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Savaysa), and the competitive thrombin inhibitor dabigatran (Pradaxa), often are preferred over warfarin because of their more predictable pharmacokinetics, comparable efficacy, comparable or lower risk of major bleeding complications, fewer drug interactions, and lack of need for frequent monitoring.
Relatively recently, edoxaban (Savaysa) by Daiichi Sankyo, Japan, has been FDA-approved in January 2015.
[35] Savaysa (edoxaban) [package insert], Daiichi Sankyo, Tokyo, Japan, http://www.accessdata.fda.gov/drugsatfda_docs/label/ 2015/206316lbl.pdf.
Most recently, he held commercial leadership roles in the launch of multiple specialty pharmaceutical products for the treatment of cardiovascular disease, including RANEXA, EFFIENT, and SAVAYSA.
Edoxaban (Savaysa) is not on the Mayo Clinic's formulary, but it is contraindicated in patients with a creatinine clearance of 95 mL/min or more.
NOACs such as Pradaxa, Eliquis, Xarelto and Savaysa provide physicians with numerous treatment options, which can be managed depending upon the patient's risk profile.
some markets and Savaysa in others (edoxaban) is an anticoagulant or a
The two anticoagulants are cangrelor (Kengreal), indicated as an adjunct to percutaneous coronary intervention to reduce the risk of myocardial infarction, and edoxaban (Savaysa), to reduce the risk of stroke and embolism in patients with atrial fibrillation and for the treatment of deep vein thrombosis and pulmonary embolism.